“You could eat a diet of bacon and diet soda all day long and you’d manage your glucose really well. But that wouldn’t be good for your whole health,” said Holly Willis, PhD, RDN, LD.
Hui Shao, MD, PhD, will discuss the financial implications these classes of agents, which have transformed diabetes care for individuals who also have cardiovascular disease, have brought to the health care system.
Shivani Agarwal, MD, MPH, Shakira Suglia, ScD, MS, and J. Frank Wharam, MD, MPH, will examine strategies to address risks influenced by social needs and to improve outcomes.
The digital diabetes care market will be worth upward of $700 million in 2022. Anne L. Peters, MD, and Kasia J. Lipska, MD, MHS, BS, will explore whether it is worth the cost.
Jennifer Sherr, MD, PhD, will highlight new glucagon formulations for treatment, and Nicole de Zoysa, DClinPsych, will review the impact of overcoming psychological obstacles on optimal hypoglycemia management.
The average ages of patients who are potentially eligible for pancreas transplantation and of potential organ donors are on the rise, but that is not the only challenge for this sector of the diabetes community, as Eelco J.P. de Koning, MD, PhD, will explain.
A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin.
Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk.
Richard I.G. Holt, PhD, FRCP, and Anne L. Peters, MD, and their writing team will summarize the key topics addressed by this trans-Atlantic collaboration.
Veterans and active-duty military personnel with diabetes can now receive self-management education in a simulated environment.